Lapatinib plus brusatol exhibited a significant effect on regressing Nrf2/HO-1 anti-oxidant and EGFR/HER2-AKT/ERK1/2 signaling pathways in SK-BR-3 and SK-OV-3 cancer cells. Here, EGFR is linked to cancer.